FDA NDA · NDA021986

DASATINIB

Sponsor: BRISTOL MYERS SQUIBB

What this page does not claim

A drug page is a reference view of public FDA data (Drugs@FDA), reproduced as published. SPEQ is not affiliated with the FDA, adds no interpretation to the record, and nothing here is medical, legal, or regulatory advice.

APPLICATION
NDA021986
TYPE
NDA
ORIGINAL APPROVAL
2006-06-28
LATEST ACTION
2026-10-16
ROUTE
ORAL
DOSAGE FORM
TABLET
MARKETING STATUS
Prescription

Products

SPRYCEL · ReferencePrescription
DASATINIB 80MG · TABLET · ORAL
SPRYCEL · ReferencePrescription
DASATINIB 70MG · TABLET · ORAL
SPRYCEL · ReferencePrescription
DASATINIB 20MG · TABLET · ORAL
SPRYCEL · ReferencePrescription
DASATINIB 140MG · TABLET · ORAL
SPRYCEL · ReferencePrescription
DASATINIB 100MG · TABLET · ORAL
SPRYCEL · ReferencePrescription
DASATINIB 50MG · TABLET · ORAL

Approval history

2026-10-16Labeling · Supplement 29 · standard — Label ↗AP
2024-07-31Labeling · Supplement 28 · standard — Letter ↗AP
2023-02-08Labeling · Supplement 27 · standard — Letter ↗AP
2021-06-29Labeling · Supplement 25 · standard — Letter ↗AP
2018-12-21Efficacy · Supplement 21 · priority — Label ↗AP
2018-11-15Labeling · Supplement 23 · standard — Label ↗AP
2017-11-09Efficacy · Supplement 20 · priority — Label ↗AP
2017-08-10Labeling · Supplement 19 · standard — Label ↗AP
2016-09-27Labeling · Supplement 18 · standard — Label ↗AP
2015-08-12Efficacy · Supplement 16 · standard — Letter ↗AP
2015-08-12Labeling · Supplement 17 · standard — Letter ↗AP
2015-01-26Manufacturing (CMC) · Supplement 15 · priorityAP
2014-04-10Labeling · Supplement 14 · standard — Letter ↗AP
2013-06-17Efficacy · Supplement 13 · standard — Label ↗AP
2011-10-07Labeling · Supplement 9 · unknown — Letter ↗AP
2011-10-07Labeling · Supplement 10 · unknown — Letter ↗AP
2010-10-28Efficacy · Supplement 7 · standard — Label ↗AP
2010-10-28Efficacy · Supplement 8 · priority — Letter ↗AP
2010-07-28Labeling · Supplement 5 · standard — Letter ↗AP
2009-05-21Efficacy · Supplement 4 · unknown — Letter ↗AP
2008-05-30Manufacturing (CMC) · Supplement 3 — Letter ↗AP
2007-11-08Efficacy · Supplement 1 · priority — Review ↗AP
2007-11-08Efficacy · Supplement 2 · unknown — Label ↗AP
2006-06-28Type 1 - New Molecular Entity · Original · priority — Label ↗AP
VIEW ON DRUGS@FDA ↗

Related on SPEQ

Pharma industry →GMP discipline →FDA drug shortages →FDA enforcement & recalls →

Source: FDA Drugs@FDA. Browse every approval SPEQ tracks →